VJHemOnc is committed to improving our service to you

COSTEM 2019 | Optimal preparative regimen for AML

VJHemOnc is committed to improving our service to you

Charles Craddock

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, evaluates whether a myeloablative conditioning regimen should be offered as a preferred treatment in fit acute myeloid leukemia (AML) patients. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter